Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat in Decompensated Heart Failure (VERCIG)
NCT07444398Phase 1Recruiting
- Start
- Jan 2026
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of Vericiguat oral suspension (Formulation 4) in heart failure (HF) (2 arms). Primary endpoints: Requirement of hospitalization for heart failure at 3 months and Death from cardiovascular event at 3 months. Started Jan 2026; status: recruiting.
02
Drugs
Vericiguat oral suspension (Formulation 4)
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT07444398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07444398.